<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01850628</url>
  </required_header>
  <id_info>
    <org_study_id>NSABP DP-1</org_study_id>
    <nct_id>NCT01850628</nct_id>
  </id_info>
  <brief_title>NSABP Biospecimen Discovery Project</brief_title>
  <official_title>NSABP Biospecimen Discovery Project</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>NSABP Foundation Inc</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Breast Cancer Research Foundation</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Washington University School of Medicine</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>NSABP Foundation Inc</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      This study is a biospecimen discovery project that will serve as a pilot for a comprehensive&#xD;
      'omics approach using fresh core biopsy tissue and blood samples for DNA and protein&#xD;
      analysis, as well as paired tumor-normal exome DNA and RNA sequencing.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      This study will be conducted at select NSABP sites where investigators are willing to give&#xD;
      paclitaxel plus trastuzumab or a trastuzumab/pertuzumab-based combination as the initial&#xD;
      component of neoadjuvant therapy as a pilot for a comprehensive 'omics approach using next&#xD;
      generation sequencing and protein expression and post-translational modification analysis&#xD;
      using mass spectrometry (MS) based and Reverse Phase Protein Array-based proteomics. Tumor&#xD;
      samples will be obtained at baseline and 48 to 72 hours after initial drug treatment to study&#xD;
      variation in the biological responses to these agents. The study of tumors both before and&#xD;
      early after the first treatment probes the biological responses to treatment and is rich&#xD;
      source of predictive biomarkers.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Active, not recruiting</overall_status>
  <start_date>July 2013</start_date>
  <completion_date type="Anticipated">February 2022</completion_date>
  <primary_completion_date type="Actual">June 2018</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Cohort</observational_model>
    <time_perspective>Prospective</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>Measure variation in biologic response by comprehensive tumor 'omics profiling in patients receiving an upfront regimen containing paclitaxel plus trastuzumab or a trastuzumab/pertuzumab-based combination</measure>
    <time_frame>blood and tissue specimens will be collected at the time of diagnosis; prior to treatment; 48 and 72 hours following first dose of treatment; and following surgery, if tumor remains.</time_frame>
  </primary_outcome>
  <number_of_groups>1</number_of_groups>
  <enrollment type="Anticipated">50</enrollment>
  <condition>Breast Cancer</condition>
  <arm_group>
    <arm_group_label>Paclitaxel plus trastuzumab or trastuzumab/pertuzumab</arm_group_label>
    <description>Patient received paclitaxel plus trastuzumab or a trastuzumab/pertuzumab-based combination administered per investigators discretion</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Paclitaxel</intervention_name>
    <arm_group_label>Paclitaxel plus trastuzumab or trastuzumab/pertuzumab</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>trastuzumab</intervention_name>
    <arm_group_label>Paclitaxel plus trastuzumab or trastuzumab/pertuzumab</arm_group_label>
    <other_name>Herceptin</other_name>
  </intervention>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>pertuzumab</intervention_name>
    <arm_group_label>Paclitaxel plus trastuzumab or trastuzumab/pertuzumab</arm_group_label>
  </intervention>
  <biospec_retention>Samples With DNA</biospec_retention>
  <biospec_descr>
    <textblock>
      fresh tumor tissue and blood samples&#xD;
    </textblock>
  </biospec_descr>
  <eligibility>
    <study_pop>
      <textblock>
        Women with locally advanced, HER2-positive breast cancer from selected sites in the United&#xD;
        States&#xD;
      </textblock>
    </study_pop>
    <sampling_method>Non-Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  The diagnosis of invasive adenocarcinoma of the breast must have been made by core&#xD;
             needle biopsy or limited incisional biopsy.&#xD;
&#xD;
          -  The breast cancer must be HER2-positive based on current ASCO/CAP (American Society of&#xD;
             Clinical Oncology/College of American Pathologists) Guideline Recommendations for&#xD;
             Human Epidermal Growth Factor Receptor 2 Testing in Breast Cancer.&#xD;
&#xD;
          -  The patient must have a mass in the breast measuring greater than or equal to 2.0 cm&#xD;
             by physical exam and/or ultrasound that is accessible and safe for repeat biopsy.&#xD;
             Patients with a diagnosis of inflammatory breast cancer are eligible if there is a&#xD;
             palpable or detectable breast mass that is accessible and safe for repeat biopsy.&#xD;
&#xD;
          -  Planned initial treatment with a combination of paclitaxel and trastuzumab or a&#xD;
             trastuzumab/pertuzumab-based combination. Schedule for paclitaxel/trastuzumab or&#xD;
             trastuzumab/pertuzumab administration is per the investigator.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Excisional biopsy or lumpectomy performed prior to registration.&#xD;
&#xD;
          -  Previous therapy with chemotherapy or targeted therapy for any malignancy.&#xD;
&#xD;
          -  Treatment, including radiation therapy (RT), chemotherapy, and/or targeted therapy,&#xD;
             administered for the currently diagnosed breast cancer prior to registration.&#xD;
&#xD;
          -  Other nonmalignant systemic disease that would preclude the patient from receiving&#xD;
             chemotherapy and targeted therapy.&#xD;
      </textblock>
    </criteria>
    <gender>Female</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Norman Wolmark, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>NSABP Foundation Inc</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>University of Florida</name>
      <address>
        <city>Gainesville</city>
        <state>Florida</state>
        <zip>32610</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Washington University School of Medicine</name>
      <address>
        <city>Saint Louis</city>
        <state>Missouri</state>
        <zip>63110</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>New York University School of Medicine</name>
      <address>
        <city>New York</city>
        <state>New York</state>
        <zip>10016</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Allegheny General Hospital</name>
      <address>
        <city>Pittsburgh</city>
        <state>Pennsylvania</state>
        <zip>15212</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Baylor College of Medicine</name>
      <address>
        <city>Houston</city>
        <state>Texas</state>
        <zip>77030</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>October 2021</verification_date>
  <study_first_submitted>May 1, 2013</study_first_submitted>
  <study_first_submitted_qc>May 6, 2013</study_first_submitted_qc>
  <study_first_posted type="Estimate">May 9, 2013</study_first_posted>
  <last_update_submitted>October 4, 2021</last_update_submitted>
  <last_update_submitted_qc>October 4, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">October 5, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>National Surgical Adjuvant Breast and Bowel Project (NSABP)</keyword>
  <keyword>paclitaxel</keyword>
  <keyword>trastuzumab</keyword>
  <keyword>pertuzumab</keyword>
  <keyword>HER2 positive (human epidermal growth factor receptor 2)</keyword>
  <keyword>Proteomics</keyword>
  <keyword>Neoadjuvant Therapy</keyword>
  <keyword>Anthracycline therapy</keyword>
  <keyword>Locally advanced</keyword>
  <keyword>Operable</keyword>
  <keyword>Biomarkers</keyword>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Paclitaxel</mesh_term>
    <mesh_term>Trastuzumab</mesh_term>
    <mesh_term>Pertuzumab</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

